Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
26 sept. 2018 06h00 HE
|
Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...